MARKET

TENX

TENX

Tenax Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.260
-0.030
-2.33%
Closed 16:00 11/26 EST
OPEN
1.260
PREV CLOSE
1.290
HIGH
1.270
LOW
1.255
VOLUME
27.28K
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
1.010
MARKET CAP
31.76M
P/E (TTM)
-0.2492
1D
5D
1M
3M
1Y
5Y
TENX: Imatinib IND Cleared & PK Study Near End
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter 2021 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported third quarter 2021 results on November 16, 2021 via the issuance of a press release...
Zacks Small Cap Research · 11/18 16:54
BRIEF-Tenax Therapeutics Says Expects Phase 3 Trial Of PAH To Begin In Q2 Of 2022
reuters.com · 11/16 13:59
Tenax Therapeutics EPS misses by $0.02
Tenax Therapeutics (NASDAQ:TENX): Q3 GAAP EPS of -$0.15 misses by $0.02. Cash and cash equivalents of $8.34M Press Release
Seekingalpha · 11/16 13:43
Tenax Therapeutics Q3 EPS $(0.15) Up From $(0.18) YoY
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.15) per share. This is a 16.67 percent increase over losses of $(0.18) per share from the same period last year.
Benzinga · 11/16 13:35
BRIEF-Tenax Therapeutics CFO Michael Jebsen To Separate From Co
reuters.com · 10/14 20:47
Tenax Therapeutics Reports Clearance Of Investigational New Drug Application For Imatinib In Pulmonary Arterial Hypertension
Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical
Benzinga · 10/06 12:34
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
MORRISVILLE, N.C., October 06, 2021--Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.
Business Wire · 10/06 12:30
ADVM, SELB and OSUR among pre market gainers
Xenon Pharmaceuticals XENE +90% on positive XEN1101 data in mid-stage focal epilepsy study Elmira Savings Bank ESBK +66% Community Bank System to buy Elmira Savings Bank in $82.8M all cash deal OpGen OPGN +30% after announcing
Seekingalpha · 10/04 12:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TENX. Analyze the recent business situations of Tenax Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TENX stock price target is 4.750 with a high estimate of 5.00 and a low estimate of 4.500.
High5.00
Average4.750
Low4.500
Current 1.260
EPS
Actual
Estimate
-1.31-0.98-0.66-0.33
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 44
Institutional Holdings: 7.76M
% Owned: 30.80%
Shares Outstanding: 25.21M
TypeInstitutionsShares
Increased
1
6.72K
New
5
4.43M
Decreased
6
130.81K
Sold Out
4
102.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
Gerald Proehl
President/Chief Executive Officer/Director
Christopher Giordano
Chief Financial Officer
Eliot Lurier
Other/Director
Stuart Rich
Independent Director
June Almenoff
Independent Director
Steven Boyd
Independent Director
Michael Davidson
Independent Director
Delcan Doogan
Independent Director
I. Keith Maher
No Data
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases of unmet medical need. The Company's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The Company's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). It is also developing an oral formulation of imatinib mesylate, a kinase inhibitor, for the treatment of pulmonary arterial hypertension (PAH).

Webull offers kinds of Tenax Therapeutics Inc stock information, including NASDAQ:TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.